The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes

Booth, I.; Clark, J. E.; LaMattina, John C.; Barth, Rolf N.; Haririan, Abdolreza; Ravichandran, Bharath

doi:10.1177/08971900211034261

Cited by 1 publication

(2 citation statements)

References 19 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This contrasts with published literature reporting a higher incidence of acute cellular rejection in HCV-NAAT-positive transplantation compared with HCV-negative donors. 30,31 CMV DNAemia rates were highest in the lung transplant population, followed by liver, kidney, and heart. At our center, low-risk CMV patients (D -/R -) receive universal herpes simplex virus prophylaxis with valacyclovir/acyclovir.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world Experiences in the Transplantation of Hepatitis C-NAAT–positive Organs

Steinbrink,

Byrns,

Berg

et al. 2023

Transplantation Direct

View full text Add to dashboard Cite

Background. Hepatitis C virus (HCV) nucleic acid amplification test (NAAT)–positive donors have increased the organ pool. Direct-acting antivirals (DAAs) have led to high rates of treatment success and sustained virologic response (SVR) in recipients with donor-derived HCV infection without significant adverse effects, although variability remains in the timing and duration of antivirals. Methods. This retrospective study analyzed all adult HCV-NAAT–negative transplant recipients who received an organ from HCV-NAAT–positive donors from November 24, 2018, to March 31, 2022, at Duke University Medical Center with protocolized delay of DAA initiation until after hospital discharge, with at least 180-d follow-up on all patients. Transplant and HCV-related outcomes were analyzed. Results. Two hundred eleven transplants (111 kidneys, 41 livers, 34 hearts, and 25 lungs) were performed from HCV-NAAT–positive donors to HCV-NAAT–negative recipients. Ninety percent of recipients became viremic within 7 d posttransplant. Ninety-nine percent of recipients were initiated on pangenotypic DAAs in the outpatient setting a median of 52 d posttransplant, most commonly with 12-wk courses of sofosbuvir–velpatasvir (lungs) and glecaprevir–pibrentasvir (heart, kidney, and liver). Ninety-seven percent of recipients had SVR after a first-line DAA; all ultimately achieved SVR at 12 wk after subsequent treatment courses. The median peak HCV RNA for all organ systems was 2 436 512 IU/mL; the median time from antiviral to undetectable RNA was 48 d, although differences were noted between organ groups. No patient deaths or graft losses were directly attributable to HCV infection. Conclusions. One hundred percent of transplant recipients of HCV-NAAT–positive organs ultimately developed SVR without significant adverse effects when HCV antivirals were initiated in the outpatient setting after transplant hospitalization, suggesting that this real-world treatment pathway is a viable option.

show abstract

Section: Discussionmentioning

confidence: 99%

“…This contrasts with published literature reporting a higher incidence of acute cellular rejection in HCV-NAAT–positive transplantation compared with HCV-negative donors. 30 , 31 …”

Section: Discussionmentioning

confidence: 99%